[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus-t2dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus-t2dm":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,108,0,25,[9,41,72,106,130,161,199,230,255,283,310,338,355,383,406,430,453,478,501,519,538,571,599,621,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645184","a-preliminary-clinical-study-protocol-for-evaluating-the-efficacy-and-safety-of-pulse-electric-field-ablation-systems-in-treating-adult-type-2-diabetes-mellitus-with-suboptimal-drug-control-100645184",false,"NCT07678866","A Preliminary Clinical Study Protocol for Evaluating the Efficacy and Safety of Pulse Electric Field Ablation Systems in Treating Adult Type 2 Diabetes Mellitus With Suboptimal Drug Control","Inclusion Criteria:\n\n1. Ages 18-70.\n2. At least 6 months prior to enrollment, the patient must have been diagnosed with type 2 diabetes mellitus.\n3. The glycated hemoglobin level is 7.5%-10.5%.\n4. BMI 2 7-40 kg\u002Fm2.\n5. Patients who, within 12 weeks prior to screening, were treated with 2-3 oral hypoglycemic agents yet still had poorly controlled blood glucose levels, and could maintain the same medication regimen throughout the trial; or those whose blood glucose control was suboptimal despite lifestyle modifications.\n6. Stable body weight (defined as a weight change of \\\u003C5% within 5 weeks prior to screening)\n7. Donation of blood is prohibited during the trial participation period.\n8. The subject must sign an Informed Consent Form (ICF), demonstrating their understanding of the purpose and procedures required for this study and their willingness to participate.\n9. Be willing and able to comply with all requirements specified in the trial, including but not limited to completing the required assessments, adhering to the visit schedule, and complying with lifestyle restrictions.\n10. Fertile female subjects must have a negative urine pregnancy test result during screening and must use contraception throughout the study period.\n\nExclusion Criteria:\n\n1. Diagnosed with type 1 diabetes mellitus.\n2. Severe diabetes-related complications such as diabetic ketoacidosis or hyperosmolar non-ketotic coma.\n3. Fasting serum C-peptide \\\u003C1 ng\u002FmL (333 pmol\u002FL).\n4. Over the past two years, insulin of any type has been used for more than 1 month (excluding treatment for gestational diabetes mellitus).\n5. History of ≥1 severe hypoglycemic episode within the past 6 months (defined as requiring assistance from a third party).\n6. Currently using a GLP-1RA or a dual GLP-6\u002FGIP agonist.\n7. Known autoimmune diseases.\n8. Previous gastrointestinal surgery that has altered the anatomical structure of the digestive tract or may limit duodenal resection, such as Billroth II, Roux-en-Y gastric bypass, gastric banding, or other similar procedures\u002Fdiseases.\n9. A known history of upper gastrointestinal structural or functional disorders may impede device passage through the upper gastrointestinal tract or increase the risk of tissue injury during endoscopic procedures, including upper gastrointestinal strictures, esophageal-gastric varices, large diverticula, or other severe esophageal, gastric, or duodenal pathologies.\n10. History of gastroparesis.\n11. Acute gastrointestinal disease has occurred within the past 7 days.\n12. A history of irritable bowel syndrome, radiation enteritis, or other inflammatory bowel diseases such as Crohns disease and celiac disease is known.\n13. Previous history of chronic or acute pancreatitis.\n14. Active hepatitis or active liver disease, or an alanine aminotransferase (ALT) level\\>3.0 times the upper limit of normal (ULN) as determined by the central laboratory during screening evaluation.\n15. Currently, vitamin K antagonists such as warfarin are being used, or oral anticoagulants (DOCA) that cannot be safely discontinued are being administered.\n16. Patients currently using P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued within 7 days prior to surgery.\n17. Nonsteroidal anti-inflammatory drugs (NSAIDs) must not be discontinued within 4 weeks after treatment. Alternative use of acetaminophen and low-dose aspirin is permitted.\n18. Systemic glucocorticoids (excluding topical, ocular, or inhaled formulations) were administered continuously for more than 12 days within 10 weeks prior to screening.\n19. Use medications known to affect gastrointestinal motility\n20. Individuals currently using weight-loss medications or over-the-counter weight-loss drugs.\n21. Participate in any structured weight loss program or endoscopic weight loss intervention within 6 months after screening.\n22. Persistent anemia, defined as hemoglobin \\\u003C10 g\u002FdL.\n23. Known hemoglobinopathies, hemolytic anemia or sickle cell anemia, or other known hemoglobin abnormalities that may interfere with HbA1c measurement.\n24. A history of blood donation or transfusion within 3 months prior to screening.\n25. Unstable or paroxysmal arrhythmia.\n26. Any of the following cardiovascular diseases occurred within 6 months prior to screening: acute myocardial infarction (AMI), cerebrovascular accident (stroke), or hospitalization due to congestive heart failure.\n27. History of valvular heart disease or chronic heart failure (NYHA class III or IV).\n28. Individuals with known immunocompromised status, including but not limited to those who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, those with clinically significant leukopenia, those who are positive for human immunodeficiency virus (HIV), or whose immune status makes them unsuitable for clinical trial participation as determined by the investigators.\n29. There is secondary hypothyroidism or poorly controlled primary hypothyroidism (TSH levels exceed the normal range during screening).\n30. During the examination, do not implant any electronic devices that cannot be turned off (such as implantable cardiac pacemakers).\n31. A duodenal or biliary stent is in place.\n32. Patients with contraindications to upper gastrointestinal endoscopy or intravenous anesthesia.\n33. Currently diagnosed with malignant tumor or with a history of malignant tumor within the preceding 5 years (excluding non-melanoma skin cancer that has received adequate treatment with no evidence of recurrence at least 3 months prior to the study intervention, or treated cervical carcinoma in situ with no evidence of recurrence at least 3 months prior to the study intervention).\n34. Breastfeeding women.\n35. The participant is currently enrolled in another ongoing clinical trial.\n36. Binge eating disorder; a history or presence of severe, progressive, or uncontrolled renal, genitourinary, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatic, neurological, psychiatric disorders, or metabolic disturbances; or any other psychological or physical condition deemed by the investigator to render the participant unsuitable for participation in the clinical trial.\n37. The patient is in critical condition or has an expected lifespan of less than 5 years.","ALL","18 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","experiment design: Single-center, single-arm, open-label trial\n\nInclusion Criteria:\n\n1. Ages 18-70.\n2. At least 6 months prior to enrollment, the patient must have been diagnosed with type 2 diabetes mellitus.\n3. The glycated hemoglobin level is 7.5%-10.5%.\n4. BMI 2 7-40 kg\u002Fm2.\n5. Patients who, within 12 weeks prior to screening, were treated with 2-3 oral hypoglycemic agents yet still had poorly controlled blood glucose levels, and could maintain the same medication regimen throughout the trial; or those whose blood glucose control was suboptimal despite lifestyle modifications.\n6. Stable body weight (defined as a weight change of \\\u003C5% within 5 weeks prior to screening)\n7. Donation of blood is prohibited during the trial participation period.\n8. The subject must sign an Informed Consent Form (ICF), demonstrating their understanding of the purpose and procedures required for this study and their willingness to participate.\n9. Be willing and able to comply with all requirements specified in the trial, including but not limited to completing the required assessments, adhering to the visit schedule, and complying with lifestyle restrictions.\n10. Fertile female subjects must have a negative urine pregnancy test result during screening and must use contraception throughout the study period.\n\nPrimary efficacy endpoint :HbA1c: The difference in HbA1c levels from the baseline period to 6 months post-treatment Observation period: 6 months postoperatively. Secondary efficacy endpoint HbA1c: The difference in HbA1c levels from the baseline period to after treatment Observation periods: 1 month, 3 months, and 12 months post-treatment. Average fasting blood glucose: The average fasting blood glucose level from the baseline period to after treatment Observation periods: 1 month, 3 months, 6 months, and 12 months post-treatment. Weight: Average weight from the baseline period to post-treatment Observation periods: 1 month, 3 months, 6 months, and 12 months post-treatment. Use of hypoglycemic agents: The incidence rate at which researchers determined the need for therapeutic intervention when glycated hemoglobin levels exceeded 8.5%.\n\nObservation periods: 1 month, 3 months, 6 months, and 12 months post-treatment. Safety Indicator 1. Adverse Events and Serious Adverse Events 2. Device defect 3. Intraoperative Instrument Performance Evaluation",[25],"Type 2 Diabetes Mellitus (T2DM)",[27,25],"pulsed electric field ablation system","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Shanghai East Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100564382","cgm-for-management-of-type-2-diabetes-in-pregnancy-100564382","NCT06628453","CGM for Management of Type 2 Diabetes in Pregnancy","Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy","CGM2","Inclusion Criteria:\n\n* Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater\n* Pregnant with viable fetus at 6 to less than 23 weeks gestation\n* Maternal age 18-50 years old\n\nExclusion Criteria:\n\n* Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions\n* Multiple gestation\n* Major fetal anomaly or two or more minor fetal anomalies\n* Planned delivery outside study consortium\n* Participating in another conflicting interventional study\n* Participation in this trial in a previous pregnancy\n* Patient unable to consent\n* Physician refusal for other reasons","FEMALE","50 Years",{"count":52,"type":21},564,"INTERVENTIONAL",[55],"NA","The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:\n\n1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose?\n2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose?\n3. What other factors increase the risk of maternal and infant complications?\n\nParticipants will:\n\n1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery\n2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis\n3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits\n4. Have umbilical cord blood collected at delivery for analysis",[25,58],"Pregnancy",[60,58,61],"Diabetes","CGM","2026-06-24",{"date":64,"type":32},"2026-06-29",{"date":66,"type":32},"2025-04-08",{"date":68,"type":21},"2029-07",{"name":70,"class":39},"University of Alabama at Birmingham",7,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":53,"phases":83,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":40},"100628559","integrating-new-skills-into-diabetes-education-with-cgm-100628559","NCT07463209","Integrating New Skills Into Diabetes Education With CGM","Integrating New Skills Into Diabetes Education With CGM (INSIDE-CGM): An Individualized CGM Integration Program for Older Adults With Diabetes","INSIDE-CGM","Participant Inclusion Criteria:\n\n* Adults 65 years and older at time of consent\n* Actively receiving care at a UNC Health or UNC Physicians Network clinic (defined as 2 or more visits in primary care, family medicine, internal medicine, geriatrics, or endocrinology clinics within the past 365 days). Locality for care is defined as residing within a 90-mile radius of UNC Main Hospital on Manning Drive in Chapel Hill, NC.\n* Using any insulin\n* No continuous glucose monitor (CGM) use within the previous 365 days\n* Willing to use a smartphone to access glucose readings using CGM phone app\n* Fluent in English\n\nParticipant Exclusion Criteria:\n\n* Clinical diagnosis of dementia, assessed through chart review and self-report on screening visit (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable)\n* Currently receiving dialysis, assessed through chart review and self-report on screening visit\n* Extreme visual or hearing impairment that would impair ability to use real-time CGM or attend and participate in an in-person or virtual group intervention session, assessed at screening visit\n* The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with life expectancy of \\\u003C1 year, assessed at screening visit\n* Unavailable for 6-week study duration (such as planned surgery or procedure, planned vacation, etc.) or unwilling to comply with study procedures\n* Not fluent in English\n* Unable to consent to recording of sessions\n\nCare Partner Inclusion Criteria:\n\n* Live in the same household as the study participant\n* Age 18 years or older\n* Fluent in English\n* Be willing to attend sessions alongside the study participant and learn how they can better support their partner participant to manage diabetes\n* Consent to recording of sessions","65 Years",{"count":82,"type":21},144,[55],"This study is designed to test the preliminary efficacy of a three-stage continuous glucose monitor (CGM) integration program for older adults who are taking insulin. This study will learn if a three-stage CGM integration program (\"intervention\") that includes sessions focused on CGM technology skills, data skills, and lifestyle skills impacts CGM wear-time, glycemic metrics, and participant-reported outcomes, compared to two standard CGM training approaches (\"comparators\").\n\nFollowing a screening visit and baseline data collection, participants will be randomized to either the intervention or one of the two comparator arms for 6 weeks. The intervention involves three educational sessions over 4 weeks. The first session will be in-person and subsequent sessions will be virtual. Participants in the intervention may receive 1-2 additional individualized training sessions to review CGM skills. The first comparator (Comparator A) will receive a one-time clinic-based CGM training. The second comparator (Comparator B) will be provided with a comprehensive informational pamphlet about CGM. All participants will complete outcomes data collection at 6 weeks.\n\nThe study will also explore participant experiences through a series of semi-structured interviews with a subset of purposively selected participants and their care partners to identify opportunities for scaling the intervention to a broader population. An extension phase of the study will evaluate long-term CGM use and associated outcomes 3- and 6-months post-intervention.\n\nLastly, we will run an additional small sub-study where consented care partners of participants will attend the intervention or comparator sessions alongside the study participant and provide care partner-specific data.",[86,87,88,89,90,91,25],"Insulin Dependent Diabetes","Diabetes (DM)","Diabetes (Insulin-requiring, Type 1 or Type 2)","Diabetes Education","Diabetes Care","Type 1 Diabetes (T1D)",[93,60,94,95,61,89],"Continuous Glucose Monitor","Insulin Dependent","Older Adults (65 years and older)","NOT_YET_RECRUITING","2026-06-23",{"date":99,"type":32},"2026-06-26",{"date":101,"type":21},"2026-06",{"date":103,"type":21},"2028-06",{"name":105,"class":39},"University of North Carolina, Chapel Hill",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":53,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100644599","phase-3-a-study-to-evaluate-the-effects-of-enicepatide-in-participants-with-obesity-or-overweight-with-or-without-type-2-diabetes-100644599","NCT07670416","A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Body mass index (BMI) ≥24.0 kilograms per meter squared (kg\u002Fm\\^2) for participants with type 2 diabetes mellitus (T2DM)\n* BMI ≥28.0 kg\u002Fm\\^2 or BMI ≥24.0 and \\\u003C28.0 kg\u002Fm\\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* History of Type 1 diabetes mellitus (T1DM)\n* Obesity induced by other endocrinologic disorders\n* Any planned major medical procedure or surgery during the study\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder\n* Any lifetime history of suicide attempt\n* History of any hematologic conditions that may interfere with HbA1c measurement\n* History of acute or chronic pancreatitis or clinically significant gallbladder disease\n* Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization\n* Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer\n* Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1\u002FGIP RAs",{"count":114,"type":21},300,[116],"PHASE3","The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.",[119,120,25],"Obesity","Overweight","2026-06-22",{"date":99,"type":32},{"date":29,"type":21},{"date":125,"type":21},"2028-04-02",{"name":127,"class":128},"Hoffmann-La Roche","INDUSTRY",3,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":138,"targetDuration":4,"studyType":53,"phases":140,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":40},"100644025","the-simplified-total-body-resistance-exercise-for-muscular-hypertrophy-for-diabetic-population-d-storm-100644025","NCT07664501","The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM)","The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM): Rationale and Study Protocol for a Randomized Controlled Trial","D-STORM","Inclusion Criteria:\n\n* Aged 18 to 65 years\n* Confirmed diagnosis of Type 2 Diabetes Mellitus\n* HbA1c between 6.5% and 13.0%\n* Not currently on insulin therapy\n* Has a primary care provider\n\nExclusion Criteria:\n\n* Age below 18 or above 65 years\n* Blood pressure 160\u002F100 mmHg or higher at screening\n* HbA1c below 6.5% or above 13.0%\n* Currently on insulin therapy\n* Pregnant or planning to become pregnant within the next 6 months\n* Serious medical conditions that would prevent safe participation in an exercise programme\n* Any physical or functional limitation that would prevent participation in resistance training\n* Underlying conditions that would not allow safe participation in the exercise intervention",{"count":139,"type":21},56,[55],"Type 2 diabetes is associated with progressive loss of muscle mass, which worsens blood sugar control and increases the risk of heart disease and disability. Resistance training (weight training) has been shown to build muscle and improve blood sugar levels, but most existing programmes use high intensities that are difficult for older or inactive people with diabetes to sustain.\n\nThis study tests a new resistance training programme called D-STORM (Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population), which uses a lower, more manageable training load designed to be safe, tolerable, and effective for adults with Type 2 diabetes who are not on insulin.\n\nParticipants will be randomly assigned to either twice-weekly D-STORM training plus their usual diabetes care, or usual care alone, for 12 weeks. The main outcome measured is change in HbA1c (a blood test reflecting average blood sugar over 3 months). Body composition, walking capacity, blood pressure, heart rate, and quality of life will also be measured.",[25,143,144],"Sarcopenia","Insulin Resistance",[146,147,148,149,150,151,152,153],"Type 2 diabetes mellitus","Resistance training","Muscular hypertrophy","Glycaemic control","HbA1c","Cardiometabolic outcomes","Randomised controlled trial","Minimal effective dose",{"date":29,"type":32},{"date":156,"type":21},"2027-01-01",{"date":158,"type":21},"2027-12-31",{"name":160,"class":39},"Universiti Teknologi Mara",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":16,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100644615","exocrine-endocrine-pancreatic-crosstalk-precision-pathways-to-reframe-diabetes-pathophysiology-100644615","NCT07670871","Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology","EXPAND","Inclusion Criteria:\n\n* Adults aged 20 to 78 years.\n* Ability and willingness to provide written informed consent.\n* Eligibility for one of the study cohorts:\n* Individuals undergoing pancreatectomy for non-endocrine pancreatic disease.\n* Individuals with pancreatic ductal adenocarcinoma undergoing pancreatectomy.\n* Individuals with chronic pancreatitis or a previous episode of acute pancreatitis.\n* Individuals at increased risk of type 2 diabetes mellitus, including impaired fasting glucose and\u002For impaired glucose tolerance.\n* Individuals with newly diagnosed type 2 diabetes mellitus.\n* Ability to undergo study-related metabolic assessments and sample collection procedures.\n\nExclusion Criteria:\n\n* Age \\\u003C20 years or \\>78 years.\n* Inability or unwillingness to provide informed consent.\n* Pregnancy or breastfeeding.\n* Diagnosis of type 1 diabetes mellitus.\n* Participation in another interventional clinical trial involving an investigational medicinal product within 30 days before enrollment.\n* Clinical conditions that preclude completion of the planned metabolic assessments.\n* Inability to comply with study procedures.","20 Years","78 Years",{"count":171,"type":21},440,"The EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic disorders.\n\nThe study will enroll adults with and without pancreatic disease, including patients undergoing pancreatic surgery, individuals with chronic pancreatitis, subjects at high risk of type 2 diabetes, and patients with newly diagnosed type 2 diabetes. Clinical, metabolic, imaging, genetic, microbiome, and molecular data will be integrated to identify distinct metabolic endotypes and to investigate the interactions between the exocrine pancreas, endocrine pancreas, and adipose tissue. The ultimate goal is to improve the understanding of diabetes pathophysiology and support the development of precision medicine approaches.",[25,174,175,176],"Chronic Pancreatitis","Prediabetes","Pancreatic Neoplasms",[178,179,180,181,182,183,184,185,186,187,188,189,190,191],"Metabolic Endotypes","Beta Cell Function","Insulin Secretion","Insulin Sensitivity","Exocrine Pancreas","Endocrine Pancreas","Pancreatic Crosstalk","Precision Medicine","Glucose Metabolism","Oral Glucose Tolerance Test","Genetic Risk Score","Fat Adipose Tissue","Hyperglycemic Clamp","Microbiome",{"date":99,"type":32},{"date":194,"type":21},"2026-09",{"date":196,"type":21},"2031-09",{"name":198,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":53,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":40},"100580375","using-continuous-glucose-monitoring-to-quantify-the-effects-of-nourishs-culturally-modified-meals-on-asian-americans-with-type-2-diabetes-100580375","NCT06836479","Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes","Validation of NOURISH Project's Culturally Tailored Meals on Postprandial Glycemic Response Using Continuous Glucose Monitoring: A Quantitative and Qualitative Study","Inclusion Criteria:\n\n* Self-identification as Asian Indian or Filipino\n* Diagnosed with T2DM\n* Can pick up meals from a designated area on the Stanford Campus\n* Willing to wear a CGM for 30 days\n\nExclusion Criteria:\n\n* Currently taking insulin, GLP -1 and SGLT 2\n* Known severe allergic reactions and\u002For food intolerances that would interfere with the ability to eat\n* Those who, in the opinion of the investigators, cannot reliably complete the study protocol.",{"count":207,"type":21},30,[55],"The investigators are hoping to determine whether tailoring the diet of someone with type 2 diabetes to their ethnic group while following American Diabetes Association guidelines can make a significant difference in their blood sugar controls. Participants will be required to wear a Continuous Glucose Monitor (CGM) for 1-month so that the investigators can compare blood sugar levels when participants are eating their routine diet vs. the culturally tailored diabetes diet.",[25,211],"Type 2 Diabetes",[211,213,214,215,216,217,218,219,220,221,222],"Asian American","Asian Indian","Filipino","Medically Tailored Meals","Culture","Culturally Tailored Meals","Continuous Glucose Monitoring","Nutritional Interventions","Dietary Adherence","Diabetes Management",{"date":62,"type":32},{"date":225,"type":32},"2026-01-08",{"date":227,"type":21},"2026-11",{"name":229,"class":39},"Stanford University",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":53,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":254},"100624795","cgm-for-insulin-treated-t2dm-during-post-discharge-transition-100624795","NCT07414277","CGM for Insulin-Treated T2DM During Post-Discharge Transition","Effects of Continuous Glucose Monitoring on Patients With Type 2 Diabetes Treated With Insulin During Post-Discharge Transition: A Multicenter Randomized Controlled Trial","TRANSIT-CGM","Inclusion Criteria:\n\n1. Age 18 to 80 years (inclusive).\n2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM).\n3. HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening\u002Fenrollment.\n4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed\u002Fconfirmed by the treating physician (principal physician).\n\nExclusion Criteria:\n\n1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment.\n2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape\u002Fadhesives.\n3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period.\n4. Currently participating in, or planning to participate in, another clinical trial.\n5. Current use of oral corticosteroid therapy, or anticipated use during the trial period.\n6. Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 times the upper limit of normal (ULN).\n7. Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m².\n8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand\u002Fcomply due to speech\u002Flanguage impairment; or presence of psychiatric disorders.","80 Years",{"count":240,"type":21},160,[55],"The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period.\n\nA total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.",[25],[245,246],"continuous glucose monitoring","insulin-treated","2026-06-21",{"date":62,"type":32},{"date":250,"type":32},"2026-05-11",{"date":158,"type":21},{"name":253,"class":39},"Shanghai 6th People's Hospital",4,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":53,"phases":264,"briefSummary":266,"conditions":267,"keywords":270,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":279,"leadSponsor":280,"locationsCount":282},"100643970","phase-4-finerenone-for-regression-of-albuminuria-in-type-2-diabetes-with-chronic-kidney-disease-100643970","NCT07667517","Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease","Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","Inclusion Criteria:\n\n* 1\\. Age \\>= 18 years at the time of signing informed consent, male or female.\n* 2\\. Type 2 diabetes mellitus.\n* 3\\. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2, and UACR 30-2000 mg\u002Fg (mean of 3 measurements).\n* 4\\. Serum potassium \\\u003C= 5.0 mmol\u002FL.\n* 5\\. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.\n* 6\\. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.\n\nExclusion Criteria:\n\n* 1\\. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.\n* 2\\. HbA1c \\>= 8.0%.\n* 3\\. On renal replacement therapy.\n* 4\\. Acute kidney injury within 180 days before the screening visit.\n* 5\\. Hepatic impairment (Child-Pugh class C).\n* 6\\. Blood pressure \\> 160\u002F100 mmHg, or systolic blood pressure \\\u003C 90 mmHg, at the screening visit.\n* 7\\. Bilateral renal artery stenosis.\n* 8\\. Known hypersensitivity to the study drug (active substance or excipients).\n* 9\\. Treatment with finerenone within 60 days before screening.\n* 10\\. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.\n* 11\\. NYHA class II-IV heart failure.\n* 12\\. Addison's disease.\n* 13\\. Gastrointestinal surgery that may affect drug absorption.\n* 14\\. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy \\\u003C 12 months).\n* 15\\. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.\n* 16\\. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.\n* 17\\. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).\n* 18\\. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.\n* 19\\. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.\n* 20\\. History of alcohol or drug abuse.\n* 21\\. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.\n* 22\\. Any other condition deemed by the investigator to make the participant unsuitable for the study.",{"count":263,"type":21},148,[265],"PHASE4","This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 and UACR 30-2000 mg\u002Fg) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (\\\u003C300 vs \\>=300 mg\u002Fg), to oral finerenone (10 or 20 mg once daily, titrated by serum potassium and eGFR) or matching placebo, on top of standard background therapy, for 180 days, followed by a 30-day off-treatment follow-up. Albuminuria regression is defined as both an improvement in Kidney Disease: Improving Global Outcomes albuminuria category, from A3 to A2 or A1, or from A2 to A1, and a more than 30% reduction in urinary albumin-to-creatinine ratio from baseline. The outcome will be reported as the percentage of participants meeting this definition at Day 180.",[268,25,269],"Albuminuria","Chronic Kidney Diseases",[271,272,273,274,275],"Finerenone","Nonsteroidal mineralocorticoid receptor antagonist","Urine albumin-to-creatinine ratio","KDIGO","Albuminuria regression","2026-06-19",{"date":29,"type":32},{"date":31,"type":21},{"date":158,"type":21},{"name":281,"class":39},"First Affiliated Hospital of Zhejiang University",13,{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":16,"minAge":290,"maxAge":238,"enrollmentInfo":291,"targetDuration":4,"studyType":53,"phases":293,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":40},"100641111","the-cognitive-protective-effect-of-vr-based-cognitive-training-in-type-2-diabetes-patients-with-mild-cognitive-impairment-100641111","NCT07650318","The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment","The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment：A Prospective, Randomized, Open-Label, Parallel-Group Pilot Study","Inclusion Criteria:\n\n1. Aged 45-80 years; gender is not restricted;\n2. Participants must meet the diagnostic criteria for diabetes outlined in the \\*Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)\\*, namely: patients exhibit typical symptoms of diabetes and meet one of the following conditions: 1) HbA1c ≥ 6.5%; 2) Fasting blood glucose ≥7.0 mmol\u002FL. Fasting is defined as no caloric intake for at least 8 hours; 3) 2-hour postprandial blood glucose ≥11.1 mmol\u002FL following an oral glucose tolerance test; 4) Random blood glucose ≥11.1 mmol\u002FL;\n3. Stable glycemic control regimen for 3 months or longer;\n4. Completed a systematic neuropsychological assessment and met the MCI diagnostic criteria outlined in the 2018 American Academy of Neurology Guidelines for Mild Cognitive Impairment, satisfying the following conditions: 1) The patient or a caregiver subjectively perceives a decline in cognitive function; 2) Assessment results indicate impairment in one or more cognitive domains; 3) There is mild impairment in complex instrumental activities of daily living, but the patient maintains independence in basic activities of daily living; 4) Does not yet meet the diagnostic criteria for dementia;\n5. Has an educational level of elementary school or higher and is able to cooperate in completing the assessment, VR training, and various examinations;\n6. Cooperate in undergoing magnetic resonance imaging (MRI) examinations;\n7. Voluntarily participates in this study, signs an informed consent form, and is able to comply with the study protocol requirements to complete follow-up.\n\nExclusion Criteria:\n\n1. Suffering from other dementia-related neurological disorders (such as Alzheimer's disease, Parkinson's disease, etc.) or severe mental illness;\n2. History of central nervous system disorders, including traumatic brain injury, intracranial hemorrhage, acute cerebral infarction, etc.;\n3. Severe sinusitis, space-occupying lesions in the nasopharynx, or congenital disorders affecting the sense of smell,or a history of trauma;\n4. Glaucoma, severe dry eye syndrome, uncorrected strabismus, severe diabetic retinopathy,or severe motion sickness, making the user unable to tolerate VR devices;\n5. History of acute diabetic complications within the past 3 months (diabetic ketoacidosis, hyperglycemic hyperosmolar state, severe hypoglycemia, etc.);\n6. Severe impairment of vital organ function, including cardiac, hepatic, or renal dysfunction;\n7. Pregnant or breastfeeding women, or women planning to become pregnant during the study;\n8. Contraindications for MRI scans, such as the presence of metallic prostheses, pacemakers, cochlear implants, or other metallic implants, or claustrophobia;\n9. Participation in other clinical trials currently or within the past 3 months;\n10. Known or suspected history of allergy to study-related materials;\n11. Currently taking medications intended to improve cognitive function.","45 Years",{"count":292,"type":21},40,[55],"A single-center, prospective, open-label, parallel-group randomized controlled trial is conducted to investigate the cognitive-protective efficacy of a novel, diabetes-specific virtual reality (VR)-based cognitive training system integrated with diet management modules, relative to frequency- and duration-matched traditional paper-and-pencil cognitive training, in adults aged 45-80 years with T2DM and amnestic\u002Fmixed mild cognitive impairment (MCI). A total of 40 eligible participants are randomly assigned 1:1 to either the intervention group (16 weeks of individualized VR training with dynamic difficulty, 2 sessions\u002Fweek, 30-60 minutes\u002Fsession) or the active control group (standardized paper-and-pencil cognitive tasks). All participants maintain stable glucose-lowering regimens for ≥3 months and receive standardized weekly diabetes health education. The primary endpoint is the between-group difference in the change in MoCA total score from baseline to the 16-week follow-up. Secondary endpoints include changes in individual cognitive domains (memory, executive function, attention, processing speed), olfactory threshold\u002Fidentification\u002Frecall, brain structural volumes and resting-state functional connectivity (assessed via 3.0T fMRI), glycemic control (HbA1c, fasting\u002Fpostprandial glucose), lipid profile, body composition, sleep quality, anxiety and depressive symptoms, and diabetes self-management behaviors. The safety and participant adherence to the VR intervention are also systematically monitored.",[25,296],"Mild Cognitive Impairment (MCI)",[298,299,300,301],"Cognition","Cognitive training","Functional MRI","Virtual reality (VR) technology","2026-06-16",{"date":304,"type":32},"2026-06-18",{"date":34,"type":32},{"date":307,"type":21},"2028-06-01",{"name":309,"class":39},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":53,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":71},"100585766","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-iris-ckd-program-2-100585766","NCT06906640","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)","IRIS-CKD","Inclusion Criteria:\n\n* (CKD Management)\n\n  * Adults with type 2 diabetes (T2D)\n  * Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)\n  * Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):\n\n    * UACR \\>300 mg\u002Fg or\n    * eGFR \\\u003C45 ml\u002Fmin\u002F1.73 m2 or\n    * UACR ≥30 mg\u002Fg with eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2\n  * Receiving \\\u003C100% GDMT at baseline. For patients with UACR \\\u003C30 mg\u002Fg, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi\u002FARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).\n\nExclusion Criteria:\n\n* (CKD Management)\n\n  * Type 1 diabetes\n  * Most recent eGFR \\\u003C20 ml\u002Fmin\u002F1.73 m2\n  * Prior kidney transplant\n  * Autosomal dominant polycystic kidney disease (ADPKD)\n  * Active pregnancy or plans for conception within 1 year",{"count":319,"type":21},420,[55],"IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[323,324,25],"Chronic Kidney Disease(CKD)","Type 2 DM",[326,327,328,211,329],"CKD","T2DM","T2D","Chronic kidney disease","2026-06-15",{"date":302,"type":32},{"date":333,"type":32},"2025-10-28",{"date":335,"type":21},"2027-04-01",{"name":337,"class":39},"Duke University",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":316,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":53,"phases":347,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":354,"locationsCount":71},"100585765","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-program-1-iris-ckd-100585765","NCT06906627","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)","Screening Program-\n\nInclusion Criteria:\n\n* Adults with type 2 diabetes (T2D)\n* Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).\n* Lack of estimated glomerular filtration rate (eGFR) and\u002For urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR\n\nExclusion Criteria:\n\n• Chronic kidney disease (CKD) diagnosis",{"count":346,"type":21},750,[55],"IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[323,324,25],[326,327,328,211,329],{"date":302,"type":32},{"date":333,"type":32},{"date":335,"type":21},{"name":337,"class":39},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":40},"100641652","validity-and-reliability-of-mixed-reality-based-functional-mobility-tests-in-type-2-diabetes-100641652","NCT07649967","Validity and Reliability of Mixed Reality-Based Functional Mobility Tests in Type 2 Diabetes","Validity and Reliability of the Mixed Reality Adaptation of the 6-Minute Walk, Timed Up and Go, and Five-Repetition Sit-to-Stand Tests in Individuals With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus by a physician,\n* Aged between 18 and 65 years,\n* Ability to ambulate independently without the use of an assistive device,\n* No participation in a structured exercise program within the previous 6 months,\n* Cognitive ability sufficient to understand and follow test instructions,\n* Visual, auditory, and vestibular functions sufficient to tolerate mixed reality applications,\n* Ability to read, understand, and follow instructions in Turkish,\n* Willingness to participate voluntarily in the study and provision of written informed consent.\n\nExclusion Criteria:\n\n* Presence of proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy,\n* Advanced peripheral neuropathy, active foot ulcer, Charcot foot, or significant sensory loss that may compromise safe test performance,\n* Presence of peripheral arterial disease,\n* Advanced renal failure, requirement for dialysis, or nephropathy that may compromise exercise safety,\n* Myocardial infarction within the previous 6 months,\n* Unstable ischemic heart disease or uncontrolled angina,\n* Resting blood pressure greater than 160\u002F100 mmHg,\n* Presence of severe musculoskeletal, neurological, or vestibular disorders that may interfere with safe test performance,\n* High risk of balance loss or spatial disorientation in the mixed reality environment due to visual, auditory, or balance impairments,\n* Cognitive, behavioral, or compliance-related problems that may prevent completion of the study procedures.",{"count":363,"type":21},75,"Type 2 Diabetes Mellitus (T2DM) is a multifaceted metabolic disease associated not only with impaired glycemic control but also with reductions in muscle strength, balance, functional mobility, and walking performance. Individuals with T2DM may experience impairments in lower extremity function, postural control, and overall functional performance, which can negatively affect activities of daily living and quality of life. Therefore, the assessment of functional performance using reliable and valid methods is important for clinical monitoring and rehabilitation planning.\n\nThe 6-Minute Walk Test (6MWT), Timed Up and Go Test (TUG), and Five-Repetition Sit-to-Stand Test (5xSTS) are widely used clinical assessments for evaluating walking capacity, functional mobility, lower extremity function, and physical performance in individuals with T2DM. Previous studies have demonstrated that these tests provide reliable and clinically meaningful measurements in this population.\n\nIn recent years, virtual and mixed reality technologies have provided opportunities to conduct assessments in a more objective, standardized, and user-friendly manner. These technologies also offer important advantages, including real-time data collection, enhanced user interaction, and potential integration into future remote assessment applications. However, evidence regarding the measurement properties of mixed reality-based adaptations of commonly used functional performance tests in individuals with T2DM remains limited.\n\nThe aim of this study is to evaluate the validity and reliability of mixed reality-based adaptations of the 6-Minute Walk Test, Timed Up and Go Test, and Five-Repetition Sit-to-Stand Test developed using the Meta Quest 3 platform. In addition, convergent validity will be examined by investigating the relationships between outcomes obtained from the mixed reality-based assessments and measures of knee extensor muscle strength and handgrip strength.\n\nThe findings of this study are expected to contribute to the development of innovative, safe, standardized, and digital approaches for assessing functional performance in individuals with Type 2 Diabetes Mellitus. Furthermore, the results may provide a scientific foundation for future digital health applications and remote assessment strategies.",[25],[367,368,369,370,371,372,373,374],"Type 2 Diabetes Mellitus","Mixed Reality","Functional Mobility","6-Minute Walk Test","Timed Up and Go Test","Five-Repetition Sit-to-Stand Test","Validity","Reliability","2026-06-11",{"date":302,"type":32},{"date":378,"type":32},"2026-06-10",{"date":380,"type":21},"2027-05-10",{"name":382,"class":39},"Selcuk University",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":390,"targetDuration":4,"studyType":53,"phases":391,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":40},"100628713","phase-2-a-study-to-evaluate-aln-4324-on-insulin-sensitivity-in-adults-with-type-2-diabetes-mellitus-100628713","NCT07465224","A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Is an adult patient with a confirmed diagnosis of T2DM\n* Has a body mass index (BMI) of ≥25 kg\u002Fm\\^2 and \\\u003C39.9 kg\u002Fm\\^2\n* Has a hemoglobin A1c (HbA1c) ≥6.5% to \\\u003C10.5%\n* Is on a stable dose of metformin\n\nExclusion Criteria:\n\n* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results\n* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods\n\nNote: other protocol defined inclusion\u002Fexclusion criteria apply",{"count":292,"type":21},[392],"PHASE2","The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM",[25],[396,397],"siRNA","RNAi",{"date":399,"type":32},"2026-06-12",{"date":401,"type":32},"2026-01-15",{"date":403,"type":21},"2027-05-28",{"name":405,"class":128},"Alnylam Pharmaceuticals",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":413,"sex":16,"minAge":17,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":53,"phases":416,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":429},"100581045","phase-1-a-study-to-evaluate-aln-4324-in-overweight-to-obese-healthy-volunteers-and-in-overweight-to-obese-patients-with-t2dm-100581045","NCT06845202","A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM","A Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)","Inclusion Criteria:\n\nPart A:\n\n* Has a body mass index (BMI) of ≥27 kg\u002Fm\\^2 and \\\u003C40 kg\u002Fm\\^2\n\nPart B:\n\n* Is an adult patient with a confirmed diagnosis of T2DM\n* Has a hemoglobin A1c (HbA1c) ≥7% to \\\u003C10.5%\n* Has a BMI of ≥25 kg\u002Fm\\^2 and \\\u003C45 kg\u002Fm\\^2\n* Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i)\n\nExclusion Criteria:\n\nPart A:\n\n* Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection\n\nPart B:\n\n* Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i\n\nNote: other protocol defined inclusion\u002Fexclusion criteria apply",true,"75 Years",{"count":82,"type":21},[417,392],"PHASE1","The purpose of this study is to:\n\n* evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324\n* evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM",[420,25],"Obese or Overweight Healthy Volunteers",[396,422],"RNAi therepeutic",{"date":399,"type":32},{"date":425,"type":32},"2025-03-03",{"date":427,"type":21},"2027-08-31",{"name":405,"class":128},22,{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":413,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":53,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":450,"locationsCount":40},"100643819","investigating-vascular-properties-of-hemi-and-spg-signals-in-individuals-with-or-at-risk-for-chronic-kidney-disease-100643819","NCT07604922","Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease","STIMULUS-CKD","Inclusion Criteria:\n\n* Common Inclusion Criteria:\n\n  * Adults aged over 18 years, of both sexes\n  * Patients eligible for or affiliated with a social security scheme\n  * Patients who have provided written informed consent to participate in the study\n\nCommon Exclusion Criteria:\n\n* Inability to give informed consent\n* Persons under legal protection (guardianship, trusteeship, or court protection)\n* Language barrier or psychological refusal to read the information\n* Medical conditions with a life expectancy \\\u003C 1 year according to clinical judgment\n* Ongoing participation restriction due to another clinical research study\n* Pregnant women (due to physiological hemodynamic changes in blood pressure and arterial stiffness during pregnancy)\n* Cardiac arrhythmias: current atrial fibrillation or high-degree atrioventricular block\n\nExclusion Criteria:\n\n* Hypertension Group\n\n  * Inclusion: Prior diagnosis of arterial hypertension\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol\n    * Type 2 diabetes Type 2 Diabetes Group\n  * Inclusion:\n  * Prior diagnosis of type 2 diabetes\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C 60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol Moderate CKD Group\n  * Inclusion:\n  * Moderate CKD (eGFR between 30 and 60 mL\u002Fmin) (CKD-EPI)\n  * Patients scheduled for arterial stiffness assessment as part of routine care\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n  * No specific exclusion criteria beyond common exclusions Severe CKD Group\n  * Inclusion:\n\n    * Severe CKD (GFR \\\u003C 30 mL\u002Fmin for ≥ 2 months)\n    * Patients scheduled for arterial stiffness assessment as part of routine care\n    * Stable cardiovascular treatment the previous 1 month\n  * Exclusion: No specific exclusion criteria beyond common exclusions20 \u002F 48 C25-07\\_Protocole\\_ V1.0\\_01.12.2025 Healthy Volunteers Group\n  * Inclusion: No documented chronic disease\n  * Exclusion:\n\n    * Moderate or severe CKD (GFR \\\u003C 60 mL\u002Fmin) (CKD-EPI)\n    * Hypertension\n    * Type 2 diabetes\n    * Stable cardiovascular treatment in the previous 1 month",{"count":438,"type":21},165,[55],"This prospective, single-center clinical investigation conducted in France will evaluate two non-invasive investigational devices (HEMI and SPG-NINOX) designed to assess microcirculation in adults. The study will include 165 participants divided into five groups (33 per group): healthy volunteers, patients with hypertension without chronic kidney disease (CKD), patients with type 2 diabetes without CKD, patients with moderate CKD, and patients with severe CKD. The primary objective is to compare baseline small vessel pressure measured with the HEMI (Multi-spectral optical system for microcirculation hemodynamics) device across groups in order to identify microvascular alterations associated with cardiometabolic and renal disease. Secondary objectives include assessment of microvascular responses after post-ischemic hyperemia, evaluation of SPG-derived (Speckle plethysmography) small vessel flow and volume parameters, comparison with reference vascular measurements (including SphygmoCor and ultra-high frequency ultrasound), and evaluation of feasibility, acceptability, and measurement reproducibility. Participation is non-randomized, based on participants' pre-existing clinical condition, and study procedures are non-invasive with an expected visit duration of approximately 60 minutes.",[442,443,25],"Chronic Kidney Disease","Hypertension (HTN)","2026-06-04",{"date":446,"type":32},"2026-06-08",{"date":330,"type":21},{"date":449,"type":21},"2028-09-15",{"name":451,"class":452},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":53,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":40},"100584262","achieving-routine-intervention-and-screening-for-emotional-health-100584262","NCT06887049","Achieving Routine Intervention and Screening for Emotional Health","ARISE: Achieving Routine Intervention and Screening for Emotional Health: Randomized Controlled Trial","ARISE","Inclusion Criteria:\n\n* Patient at a participating clinic\n* Type 2 diabetes\n* Adult (18 years or older)\n* A1C \\> 8%\n\nExclusion Criteria:\n\n* Pregnant",{"count":462,"type":21},1250,[55],"The purpose of this project is to evaluate the effectiveness of diabetes distress screening and intervention on patients with type 2 diabetes mellitus (T2DM).",[25,466],"Diabetes Distress",[468],"diabetes distress screening","2026-06-03",{"date":471,"type":32},"2026-06-05",{"date":473,"type":32},"2026-03-10",{"date":475,"type":21},"2028-09",{"name":477,"class":39},"University of Chicago",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":487,"conditions":488,"keywords":491,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":500,"locationsCount":429},"100643538","diagnostic-value-of-the-liver-inflammation-index-for-mash-in-patients-with-t2dm-and-mafld-100643538","NCT07632677","Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD","A Multicenter Cross-Sectional Study Evaluating the Diagnostic Accuracy of the Liver Inflammation Index for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Patients With Concurrent Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease","Inclusion Criteria:\n\n1. Adults aged ≥18 years, with no restrictions on sex;\n2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition).\n\nExclusion Criteria:\n\n1. Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination;\n2. Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, alcoholic liver disease, or other chronic liver diseases;\n3. History of hepatic decompensation;\n4. History of hepatectomy or liver transplantation;\n5. History of other malignancies;\n6. Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion;\n7. History of transjugular intrahepatic portosystemic shunt (TIPS);\n8. Occurrence of acute hepatitis during follow-up (defined as alanine aminotransferase levels \\>5 times the upper limit of normal) or acute-on-chronic liver failure (ACLF);\n9. Clinical or subclinical hypothyroidism or hyperthyroidism.",{"count":486,"type":21},10000,"This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).",[25,489,490],"MASH - Metabolic Dysfunction-Associated Steatohepatitis","Metabolic Dysfunction-associated Fatty Liver Disease",[367,492,493,494],"MASH","MAFLD","Liver inflammation index","2026-06-02",{"date":446,"type":32},{"date":498,"type":21},"2026-05-15",{"date":158,"type":21},{"name":309,"class":39},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":53,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":517,"locationsCount":71},"100640365","phase-3-balance-dm2-study-of-bofanglutide-in-adults-with-type-2-diabetes-100640365","NCT07628985","BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes","BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) in Latin American Adults With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Adults aged 18 years and older who agree to participate in the study by voluntarily signing the Informed Consent Form.\n* Adult participants of either male or female sex.\n* Diagnosis of type 2 diabetes mellitus (T2DM) with a duration greater than 6 months, established according to the diagnostic and classification criteria for diabetes mellitus of the World Health Organization (WHO) in 1999, as well as the supplementary WHO diagnostic criteria of 2011, and in accordance with the widely accepted clinical criteria of the American Diabetes Association.\n* Background treatment with metformin monotherapy, at a stable dose for at least 90 days prior to screening, at a dose ≥1500 mg\u002Fday or at the maximum tolerated dose (MTD; ≥1000 mg\u002Fday), with no planned changes during the study.\n* HbA1c determined by central laboratory during the screening period ≥7.0% and ≤10.5%.\n* Fasting plasma glucose (FPG) during screening \\\u003C270 mg\u002FdL.\n* Body mass index (BMI) ≥27 kg\u002Fm².\n* Stable body weight prior to screening, defined as a change ≤5% in body weight during the previous 3 months.\n* Women of childbearing potential must have a negative pregnancy test during screening and at the baseline visit; must not be breastfeeding; must have no plans for pregnancy from signing the ICF until 6 months after the last dose of study treatment; and must agree to use effective contraceptive methods during this period.\n\nMen must have no plans for sperm donation during the same period.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to GLP-1 type drugs or any of their excipients; or presence of contraindications for this type of medication.\n* Participation in clinical trials of other drugs or devices and having received treatment within the 3 months prior to the screening period.\n* Conditions that may cause significant instability in body weight or glycemic control within the 3 months prior to screening, including, but not limited to:\n\n  * Major surgery or surgical procedures with the potential to significantly alter body weight, intake, absorption, gastric emptying, mobility, or metabolic recovery.\n  * Current use of non-antidiabetic medications that affect body weight.\n  * Participation in weight loss programs that are not in the maintenance phase.\n* Use, initiation, discontinuation, or relevant dose change of concomitant medications that, in the investigator's judgment, may significantly affect glycemic control or body weight, including, but not limited to, chronic systemic glucocorticoids, antipsychotics, antiepileptics, or other drugs with relevant metabolic effects, within the 12 weeks prior to the screening period, or plans to initiate or modify such treatments during the study.\n* History of alcohol or drug abuse, including, but not limited to, amphetamines, benzodiazepines, marijuana, cocaine, methadone, and morphine-like drugs, within the 6 months prior to screening, determined by medical history or positive substance abuse screening test results (urine).\n* Previous antidiabetic treatment with:\n\n  * Insulin for more than 14 consecutive days within the year prior to screening (insulin treatment for gestational diabetes mellitus is not considered under this criterion).\n  * GLP-1 receptor agonists within the 6 months prior to screening.\n  * DPP-4 inhibitors ≤3 months prior to screening.\n* Use of medications such as growth hormone, or others that, in the investigator's judgment, may affect insulin levels, within the 3 months prior to screening.\n* History of diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar non-ketotic coma within the 6 months prior to screening.\n* T2DM complications such as proliferative retinopathy or maculopathy that is unstable or has required treatment; severe diabetic neuropathy, intermittent claudication, or diabetic foot within the 6 months prior to screening.\n* Severe hypoglycemia (Grade 3) within the 6 months prior to screening; or ≥3 episodes of hypoglycemia (blood glucose ≤70 mg\u002FdL) within the month prior to screening; or recurrent symptoms related to hypoglycemia.\n* Severe trauma, serious infection, or major surgery that, in the investigator's judgment, may affect glycemic control, within the month prior to screening.\n* Serum calcitonin ≥50 pg\u002FmL during screening.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B (MEN 2A\u002F2B), or diagnosis of other malignant neoplasms within the last 5 years.\n* Uncontrolled hyperthyroidism or hypothyroidism. Subjects who have received stable thyroxine replacement treatment for ≥3 months prior to screening and whose TSH, FT3, and FT4 levels are within normal ranges are exempt from this criterion.\n* History of acute or chronic hepatitis, acute or chronic pancreatitis, symptomatic gallbladder disease (for example, multiple gallstones), pancreatic injury, or other high-risk factors that may predispose to the development of pancreatitis.\n* Uncontrolled arterial hypertension, defined as systolic blood pressure (SBP) ≥160 mmHg and\u002For diastolic blood pressure (DBP) ≥100 mmHg at screening.\n* History of hospitalization for severe cardiovascular disease (including, among others, acute myocardial infarction, unstable angina, cerebrovascular disease, or peripheral vascular disease) or sequelae of cerebrovascular disease within the 6 months prior to screening; presence of a cardiac pacemaker, second\u002Fthird-degree atrioventricular block, long QT syndrome, QTc ≥450 ms on 12-lead ECG without pacemaker; NYHA class III or IV heart failure; or any other clinically significant cardiac abnormality that, in the investigator's judgment, makes the subject unsuitable for the study.\n* Clinically significant hematologic disorders or any condition that may affect erythrocyte half-life or stability, and therefore interfere with interpretation of glycated hemoglobin (HbA1c), including, but not limited to, aplastic anemia, myelodysplastic syndrome, thalassemia, sickle cell anemia, hemolytic anemia, or any disease causing hemolysis or erythrocyte instability (including malaria or Henoch-Schönlein purpura). Likewise, blood donation or blood loss \\>400 mL or blood transfusion within the 3 months prior to screening.\n* Clinically significant gastric emptying abnormalities (for example, gastric outlet obstruction), severe chronic gastrointestinal disorders (for example, active ulcers within the last 6 months), prolonged use of drugs that directly affect gastrointestinal motility (including, but not limited to, domperidone, mosapride, cisapride), or gastrointestinal surgery within the 6 months prior to screening, which, in the investigator's judgment, make the subject unsuitable to participate in the study.\n* Clinically significant laboratory abnormalities, including:\n\n  * ALT or AST ≥2.5 times the upper limit of normal (ULN).\n  * Fasting triglycerides \\>500 mg\u002FdL.\n  * Amylase and\u002For lipase ≥1.5 times the ULN.\n  * Fasting blood glucose \\>270 mg\u002FdL.\n  * Estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m².\n* Evidence of clinically relevant active infection at screening, defined as:\n\n  * Hepatitis B virus (HBV): positive surface antigen (HBsAg) accompanied by detectable viral load (HBV DNA above the laboratory lower limit of detection).\n  * Hepatitis C virus (HCV): positive antibodies with detectable viral load (HCV RNA above the laboratory lower limit of detection). Subjects with resolved infection (documented negative RNA) may be included.\n  * Human immunodeficiency virus (HIV): confirmed infection with clinical impact or unstable treatment that, in the investigator's judgment, may interfere with subject safety or study participation.\n  * Treponema pallidum: positive serology confirmed as active infection by confirmatory tests.\n* History of organ transplantation, or acquired or congenital immune system disorders.\n* Previous history of psychiatric disorders such as schizophrenia, bipolar disorder, previous suicidal tendency, etc., or use of psychiatric medications that, in the investigator's judgment, may interfere with subject participation in the study or protocol compliance.\n* Any clinical condition or circumstance that, in the investigator's judgment, may compromise subject safety, protocol compliance, or the validity and interpretability of study data.",{"count":509,"type":21},374,[116],"The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy. The main questions it aims to answer are:\n\nDoes Bofanglutide (GZR18) provide glycemic control comparable to Semaglutide based on changes in HbA1c? Is Bofanglutide (GZR18) safe and well tolerated in the study population? Can participants achieve glycemic targets and improve metabolic outcomes during treatment?\n\nResearchers will compare participants receiving Bofanglutide (GZR18) with participants receiving Semaglutide to evaluate their effects on glycemic control, metabolic outcomes, safety, quality of life, and treatment satisfaction.\n\nParticipants will:\n\nBe randomly assigned in a 1:1 ratio to receive Bofanglutide (GZR18) or Semaglutide.\n\nContinue stable metformin monotherapy during the study. Receive subcutaneous study treatment with dose escalation according to the study protocol.\n\nParticipate in 30 weeks of active treatment. Attend scheduled study visits, laboratory assessments, and safety evaluations. Complete questionnaires related to quality of life and treatment satisfaction.",[25],{"date":471,"type":32},{"date":194,"type":21},{"date":516,"type":21},"2027-10",{"name":518,"class":128},"Carnot Laboratories",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":413,"sex":526,"minAge":17,"maxAge":290,"enrollmentInfo":527,"targetDuration":4,"studyType":53,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":536,"locationsCount":4},"100638341","phase-1-a-phase-i-study-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-single-subcutaneous-ubt38006-injection-in-healthy-adult-males-100638341","NCT07630233","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of UBT38006 Injection in Healthy Adult Male Subjects","Inclusion Criteria:\n\n* Aged 18-45 years (inclusive) at the time of informed consent form (ICF) signing;\n* Sex: Male;\n* Body weight ≥50.0 kg and body mass index (BMI) between 19.0-24.0 kg\u002Fm² (BMI = weight \\[kg\\] \u002F height² \\[m²\\]), inclusive, at Screening;\n* Fasting plasma glucose (FPG) between 3.9-6.1 mmol\u002FL (exclusive of boundary values) at Screening; 2-hour plasma glucose \\\u003C7.8 mmol\u002FL on oral glucose tolerance test (OGTT) at Screening; insulin release test (IRT) results normal, or abnormal but judged by the Investigator as not clinically significant (NCS)at Screening; glycated hemoglobin (HbA1c) ≤6.0% at Screening;\n* The subject (including his partner) is willing to use adequate and effective contraception voluntarily from Screening through 3 months after administration of the investigational medicinal product (IMP) (see Appendix 2 for details), and has no plan to donate sperm within 3 months after IMP administration;\n* The subject is able to communicate well with the Investigator, has adequate understanding of this study, participates voluntarily, understands and complies with all study requirements, and provides written informed consent.\n\nExclusion Criteria:\n\n* History of severe hypersensitivity (e.g., allergy to three or more allergens, allergic asthma involving the lower respiratory tract, or allergy requiring systemic corticosteroid therapy) or known hypersensitivity to any component of the investigational medicinal product;\n* History of severe or currently clinically significant disease\u002Fcondition (including but not limited to diseases of the nervous, cardiovascular, respiratory, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, metabolic, and skeletal systems, history of malignancy, or neurological or psychiatric disease\u002Fcondition);\n* History of orthostatic hypotension, syncope, or amaurosis, or first-degree relative with history of diabetes mellitus;\n* Laboratory abnormalities (hematology, blood chemistry, coagulation function, thyroid function, urinalysis, stool routine, etc.) at Screening that are judged by the Investigator as clinically significant;\n* Positive insulin autoantibody (IAA) at Screening;\n* Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody, or Treponema pallidum antibody at Screening;\n* History of drug abuse, or positive urine drug screen prior to randomization;\n* Clinically significant abnormalities on physical examination, electrocardiogram (ECG), or vital signs (body temperature, pulse, blood pressure);\n* Use of insulin-containing agents within 3 months prior to dosing, or use of any other medication (including traditional Chinese medicine, over-the-counter drugs, etc.) within 30 days prior to dosing;\n* Vaccination with any vaccine within 1 month prior to dosing;\n* History of surgery within 3 months prior to dosing, or planned surgery during the entire study period;\n* History of blood loss or blood donation exceeding 200 mL within 3 months prior to dosing (calculated from the day before dosing);\n* Hemoglobin below the lower limit of normal (LLN);\n* Participation in other interventional clinical trials within 3 months prior to dosing (except for subjects who only underwent screening but were not enrolled, or were enrolled but did not receive treatment);","MALE",{"count":528,"type":21},43,[417],"This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design. Insulin degludec injection serves as the active control and is administered in an open-label manner.\n\nThe study will be conducted across 5 cohorts, comprising 4 dose-escalation cohorts of UBT38006 (1, 3, 6, and 12 nmol\u002Fkg) and 1 active control cohort of insulin degludec (0.4 U\u002Fkg \\[2.4 nmol\u002Fkg\\]). The safety and tolerability (including local tolerability) as well as the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single subcutaneous doses of UBT38006 injection will be evaluated in healthy adult male subjects.\n\nIn Cohort 1 (1 nmol\u002Fkg), subjects will be randomized in a 4:1 ratio to receive either UBT38006 injection or placebo. In Cohorts 2-4 (3, 6, and 12 nmol\u002Fkg), subjects will be randomized in an 8:2 ratio to receive the corresponding dose of UBT38006 injection or placebo. Subjects in Cohort 5 (insulin degludec active control) will receive 0.4 U\u002Fkg (2.4 nmol\u002Fkg) insulin degludec injection. Cohorts 1-4 will follow a double-blind design, while Cohort 5 will be open-label.",[25],{"date":471,"type":32},{"date":276,"type":21},{"date":535,"type":21},"2026-10-25",{"name":537,"class":128},"The United Bio-Technology (Hengqin) Co., Ltd.",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":546,"targetDuration":4,"studyType":53,"phases":547,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":568,"locationsCount":570},"100638643","phase-4-sglt2-inhibitors-on-coronary-atherosclerosis-progression-via-perivascular-adipose-tissue-in-diabetes-100638643","NCT07614230","SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes","Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE Trial","SCOPE","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Confirmed diagnosis of type 2 diabetes mellitus with SCORE2-Diabetes risk score \\>10%.\n* Stable angina pectoris.\n* Coronary CT angiography (CCTA) demonstrating 50%-90% stenosis in at least one coronary vessel with diameter ≥2.5 mm.\n* CT-derived fractional flow reserve (CT-FFR) \\>0.8 in the target vessel.\n* Stable standard therapy for diabetes and cardiovascular disease, with no changes in SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors within the past 4 weeks.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) with stenting, prosthetic valve replacement, or permanent pacemaker implantation.\n* New York Heart Association (NYHA) functional class III or IV heart failure. Acute myocardial infarction within the previous 30 days.\n* Known allergy to iodinated contrast media or other contraindications to CCTA. Severe arrhythmia or coronary artery calcium (CAC) score \\>400.\n* Estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m². History of serious adverse reactions to SGLT2 inhibitors.\n* Pregnancy, lactation, or planned pregnancy during the study period. Severe liver dysfunction (Child-Pugh class C).\n* Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.",{"count":82,"type":21},[265],"This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup in the coronary arteries) in patients with type 2 diabetes. The effect may be mediated by improving the function of perivascular adipose tissue. A total of 144 adults with type 2 diabetes and stable coronary artery disease will be randomly assigned to receive either dapagliflozin plus standard diabetes and cardiovascular care (intervention group) or standard care alone (control group) for 18 months. Serial coronary CT angiography and other assessments will be performed to evaluate changes in coronary plaque volume, CT-derived fractional flow reserve, perivascular fat radiomics score, and various metabolic and inflammatory markers, to determine whether SGLT2 inhibition reduces cardiovascular risk.",[25,550,551],"Coronary Artery Disease","Atherosclerosis",[553,554,555,556,211,557,558,559,560,561],"SGLT2 Inhibitors","Dapagliflozin","Perivascular Adipose Tissue","Coronary Atherosclerosis","Plaque Progression","Coronary CT Angiography","Cardiovascular Risk","PVAT","Randomized Controlled Trial","2026-05-25",{"date":564,"type":32},"2026-05-29",{"date":566,"type":32},"2026-01-01",{"date":36,"type":21},{"name":569,"class":39},"Junjie Yang",2,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":579,"targetDuration":4,"studyType":53,"phases":581,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":40},"100640729","mindfulness-training-in-type-2-diabetes-100640729","NCT07617766","Mindfulness Training in Type 2 Diabetes","The Effect of Mindfulness-Based Self-Management Education on Diabetes-Related Difficulties and Empowerment in Individuals With Type 2 Diabetes","MindfulT2DCA","Inclusion Criteria:\n\n* Aged between 18 and 65 years.\n\nDiagnosed with Type 2 diabetes mellitus.\n\nLiterate (able to read and write).\n\nHas access to and is able to actively use a smartphone or internet.\n\nNo diagnosed mental or cognitive impairment.\n\nWilling to participate voluntarily and provide informed consent.\n\nExclusion Criteria:\n\n* Previously received structured education related to their diabetes.\n\nPregnant.\n\nCurrently participating in another research study.\n\nHospitalized due to diabetes-related complications.\n\nUnable to complete the education program.",{"count":580,"type":21},70,[55],"This study aims to evaluate the effects of mindfulness-based self-management education on diabetes-related difficulties and empowerment in individuals with type 2 diabetes. Participants will receive a structured education program designed to improve self-care behaviors, emotional well-being, and confidence in managing their condition.\n\nThe program includes mindfulness practices, diabetes self-management education, and supportive group sessions. Outcomes such as diabetes distress, self-management behaviors, and patient empowerment will be measured before and after the intervention.\n\nThe findings of this study are expected to contribute to improving patient-centered care and supporting individuals with type 2 diabetes in managing their health more effectively.",[25],[585,586,587,588,589,590],"Mindfulness","Type 2 diabetes","Self-management education","Patient empowerment","Behavioral intervention","Diabetes difficulties","2026-05-24",{"date":34,"type":32},{"date":594,"type":21},"2026-05",{"date":596,"type":21},"2027-05",{"name":598,"class":39},"Ataturk University",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":414,"enrollmentInfo":606,"targetDuration":608,"studyType":22,"phases":4,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":40},"100626255","the-effect-of-local-corticosteroid-injection-in-carpal-tunnel-syndrome-patients-with-type-2-diabetes-100626255","NCT07433257","The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes","The Effect of Local Corticosteroid Injection on Electrophysiological and Ultrasonographic Findings in Carpal Tunnel Syndrome Patients With Type 2 Diabetes","Inclusion Criteria\n\n* Carpal Tunnel Syndrome with Type 2 Diabetes Mellitus Group (Group 1):\n\n  * Age between 18 and 75 years\n  * Presence of clinical symptoms compatible with carpal tunnel syndrome (e.g., pain, paresthesia, numbness) for at least 3 months\n  * Patients diagnosed with mild-to-moderate carpal tunnel syndrome based on electrophysiological findings\n  * Diagnosis of type 2 diabetes mellitus\n  * Regulated blood glucose levels, defined as hemoglobin A1c (HbA1c) \\\u003C 7%\n* Idiopathic Carpal Tunnel Syndrome Group (Group 2):\n\n  * Age between 18 and 75 years\n  * Presence of clinical symptoms consistent with carpal tunnel syndrome (e.g., pain, paresthesia, numbness) for at least 3 months\n  * Patients diagnosed with mild-to-moderate carpal tunnel syndrome based on electrophysiological findings\n  * No diagnosis of diabetes mellitus\n\nExclusion Criteria\n\n* Severe carpal tunnel syndrome based on electrophysiological findings\n* Presence of polyneuropathy, cervical radiculopathy, brachial plexopathy, or thoracic outlet syndrome\n* Uncontrolled blood glucose levels in the diabetic group (hemoglobin A1c ≥ 7%)\n* Presence of another systemic disease, other than diabetes mellitus, that may cause carpal tunnel syndrome\n* Presence of a rheumatological disease\n* History of wrist surgery\n* Less than 6 months since a local corticosteroid injection for carpal tunnel syndrome\n* Less than 3 months since completion of a physical therapy program for carpal tunnel syndrome\n* Infection at the intended injection site\n* Presence of malignancy\n* Pregnancy",{"count":607,"type":21},60,"12 Weeks","Our study was planned as a prospective observational study aiming to compare the post-intervention recovery process between patients with carpal tunnel syndrome (CTS) and diabetes mellitus and patients with idiopathic carpal tunnel syndrome without diabetes mellitus. Patients who presented to the Physical Medicine and Rehabilitation outpatient clinic with clinical symptoms consistent with carpal tunnel syndrome and who were diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological findings and who received corticosteroid + local anesthetic injection will be included in the study. Data from patients who meet the inclusion and exclusion criteria will be included in the study. Patients' demographic and clinical data will be recorded. Records will be taken before treatment and at 4 and 12 weeks after treatment.",[611,25],"Carpal Tunnel Syndrome (CTS)","2026-05-23",{"date":614,"type":32},"2026-05-27",{"date":616,"type":32},"2026-03-01",{"date":618,"type":21},"2026-07-31",{"name":620,"class":39},"Haydarpasa Numune Training and Research Hospital",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":53,"phases":631,"briefSummary":632,"conditions":633,"keywords":635,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":652,"locationsCount":40},"100639892","validation-of-the-snouda-metabolic-score-for-phenotyping-and-guiding-reversal-in-type-2-diabetes-100639892","NCT07606872","Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes","A Prospective Interventional Clinical Validation Study of the Snouda Metabolic Score (SMS) as a Phenotyping and Protocol-Targeting Instrument in Adults With Type 2 Diabetes Mellitus","SMS-VAL","Inclusion Criteria:\n\n* Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider\n* Age 18 years or older\n* HbA1c between 6.5% and 11.0% at baseline\n* Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas)\n* Ability to access and use the diabetesreversal.io digital platform\n* Willingness to perform daily self-monitoring of blood glucose\n* Willingness to complete laboratory blood tests (Genesis Biomarker Panel) at baseline and Week 24 at own expense\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA)\n* Currently pregnant or breastfeeding\n* Currently using insulin therapy\n* Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide)\n* HbA1c greater than 11.0% at baseline\n* History of severe hypoglycemia requiring third-party assistance in the past 12 months\n* Active malignancy or receiving chemotherapy or radiation therapy\n* Severe renal impairment (eGFR less than 30 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment\n* Active eating disorder\n* Any condition that in the opinion of the investigator would make participation unsafe or interfere with study completion",{"count":630,"type":21},150,[55],"This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.\n\nOnce classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.\n\nThe main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.\n\nThe study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.",[25,144,634],"Metabolic Syndrome",[636,637,638,639,640,641,642,643,644,645],"Diabetes reversal","Metabolic phenotyping","Snouda Metabolic Score","Lifestyle intervention","HbA1c reduction","Intermittent fasting","Low-carbohydrate diet","Chronic inflammation","Mitochondrial dysfunction","Gut microbiome","2026-05-19",{"date":648,"type":32},"2026-05-26",{"date":101,"type":21},{"date":651,"type":21},"2027-03",{"name":653,"class":39},"Salah Snouda",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":16,"minAge":290,"maxAge":18,"enrollmentInfo":662,"targetDuration":4,"studyType":53,"phases":664,"briefSummary":665,"conditions":666,"keywords":673,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":686,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":40},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.",{"count":663,"type":21},216,[55],"Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[211,667,668,669,670,671,25,367,672],"Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes (T2DM)",[674,675,676,677,678,679,680,681,682,683,684,685],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine",{"date":646,"type":32},{"date":688,"type":32},"2025-10-14",{"date":690,"type":21},"2027-02-16",{"name":692,"class":39},"University of Pennsylvania"]